These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 19093126)
21. [Immunology in clinical practice IX. Systemic vasculitis]. Kallenberg CG; Tervaert JW Ned Tijdschr Geneeskd; 1998 Jan; 142(3):118-23. PubMed ID: 9557008 [TBL] [Abstract][Full Text] [Related]
22. Pathogenic role and clinical relevance of antineutrophil cytoplasmic antibodies in vasculitides. Shovman O; Gilburd B; Zandman-Goddard G; Sherer Y; Shoenfeld Y Curr Rheumatol Rep; 2006 Aug; 8(4):292-8. PubMed ID: 16839508 [TBL] [Abstract][Full Text] [Related]
23. Role of antineutrophil cytoplasmic antibodies and glomerular basement membrane antibodies in the diagnosis and monitoring of systemic vasculitides. Sinclair D; Stevens JM Ann Clin Biochem; 2007 Sep; 44(Pt 5):432-42. PubMed ID: 17761028 [TBL] [Abstract][Full Text] [Related]
29. [What are vasculitides?]. Somer T; Sariola H Duodecim; 1995; 111(10):949-51. PubMed ID: 9081831 [No Abstract] [Full Text] [Related]
30. Glomerulonephritis in the vasculitides: advances in immunopathology. Hauer HA; Hagen EC; de Heer E; Bruijn JA; Bajema IM Curr Opin Rheumatol; 2003 Jan; 15(1):17-21. PubMed ID: 12496505 [TBL] [Abstract][Full Text] [Related]
31. Bilateral Vision Loss with p-ANCA Associated Lymphocytic Vasculitis. Osborn AR; Jun S; Miller DC; Jun B Ocul Immunol Inflamm; 2020; 28(1):54-57. PubMed ID: 30427747 [No Abstract] [Full Text] [Related]
33. New insights into the pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis. Kallenberg CG; Rarok A; Stegeman CA; Limburg PC Autoimmun Rev; 2002 Feb; 1(1-2):61-6. PubMed ID: 12849060 [TBL] [Abstract][Full Text] [Related]
34. Diagnostic significance of ANCA in vasculitis. Csernok E; Lamprecht P; Gross WL Nat Clin Pract Rheumatol; 2006 Apr; 2(4):174-5. PubMed ID: 16932679 [No Abstract] [Full Text] [Related]
35. [Antineutrophil cytoplasmic antibodies (ANCA). Their contribution to the pathogenesis of vasculitis]. Mirapeix E Med Clin (Barc); 1998 Jun; 110(20):778-80. PubMed ID: 9666419 [No Abstract] [Full Text] [Related]
36. Primary vasculitides and vasculitis confined to skin: clinical features and new pathogenic aspects. Csernok E; Gross WL Arch Dermatol Res; 2000 Sep; 292(9):427-36. PubMed ID: 11000286 [TBL] [Abstract][Full Text] [Related]
37. What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. de Groot K; Jayne D Clin Nephrol; 2005 Dec; 64(6):480-4. PubMed ID: 16370164 [TBL] [Abstract][Full Text] [Related]
38. Evidence-based management of ANCA vasculitis. Carruthers D; Sherlock J Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):367-78. PubMed ID: 19508944 [TBL] [Abstract][Full Text] [Related]
39. Antineutrophil cytoplasmic antibodies in the classification of vasculitis. Niles JL Annu Rev Med; 1996; 47():303-13. PubMed ID: 8712783 [TBL] [Abstract][Full Text] [Related]
40. Anti-endothelial cell antibodies in patients with AAV: the relationship with ANCA? Comment on: Identification of target antigens of anti-endothelial cell antibodies in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides: a proteomic approach. Gou SJ; Fu P Clin Immunol; 2014 Oct; 154(2):188. PubMed ID: 25108051 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]